Cyclooxygenase-2 (Cox-2) expression in lymphomas

Leukemia and Lymphoma

Volumn 45, Issue 7, 2004, Pages 1395-1399

  Hazar, Burhan ^a   Ergin, Melek ^b   Seyrek, Ertuǧrul ^a   Erdoǧan, Şeyda ^b   Tuncer, Ilhan ^b   Hakverdi, Sibel ^c  

^a MERSIN UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^c ADANA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Cyclooxygenase 2 (Cox 2); Lymphoma and prognosis

Indexed keywords

BLEOMYCIN; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROSTAGLANDIN SYNTHASE INHIBITOR; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME INHIBITION; FEMALE; FOLLICULAR LYMPHOMA; HISTOPATHOLOGY; HODGKIN DISEASE; HOSPITAL ADMISSION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHODGKIN LYMPHOMA; ONCOLOGY; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; UNIVERSITY HOSPITAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; ISOENZYMES; LIFE TABLES; LYMPHOMA; LYMPHOMA, NON-HODGKIN; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PREDNISONE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SURVIVAL ANALYSIS; VINBLASTINE; VINCRISTINE;

EID: 2542587682     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190310001654032     Document Type: Article

References (30)

1. Evans, L.S. and Hancock, B.W. (2003) "Non-Hodgkin lymphoma", Lancet, 362, 139-146.
2. Shipp, M.A., Harrington, D.L. and Anderson, J. (1993) "Development of practice model for aggressive lymphoma", N. Engl. J. Med., 329, 987-994.
3. Dubois, R.N., Arramson, S.B., Crofford, L., et al. (1998) "Cyclooxygenase in biology and disease", FASEB J., 12, 1063-1073.
4. Steinbach, G., Lynch, P.M., Phillips, R., et al. (2000) "The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis", N. Engl. J. Med., 342, 1946-1952.
5. Thun, M.J., Namboodiri, M.M. and Heath, C.W.J. (1991) "Aspirin use and reduced risk of fatal colon cancer", N. Engl. J. Med., 325, 1593-1596.
6. Rosenberg, L., Louik, C. and Shapiro, S. (1998) "Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma", Cancer, 82, 2326-2333.
7. Williams, C.S., Watson, A., Sheng, H., et al. (2000) "Celecoxib prevents tumor growth in vitro without toxicity to normal gut: lack of correlation between in vitro and in vivo models", Cancer Res., 60, 6045-6051.
8. Petersen, C., Petersen, S., Milas, L., et al. (2000) "Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor", Clin. Cancer Res., 6, 2513-2520.
9. Marrogi, A., Pass, H.I., Khan, M., et al. (2000) "Human mesothelioma samples overexpress both cyclooxygenase-2 (Cox-2) and inducible nitric oxide synthase (NOS2): In vitro antiproliferative effects of a Cox-2 inhibitor", Cancer Res., 60, 3696-3700.
10. Marrogi, A., Travis, W.D., Welsh, J.A., et al. (2000) "Nitric oxide synthase, cyclooxygenase-2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma", Clin. Cancer Res., 6, 4739-4744.
11. Altorki, N.K., Keresztes, R.S., Port, J.L., et al. (2003) "Celecoxib, a selective cyclooxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early stage non-small cell lung cancer", J. Clin. Oncol., 21, 2645-2650.
12. Uefuji, K., Ichikura, T. and Mochizuki, H. (2000) "Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer", Clin. Cancer Res., 6, 135-138.
13. Cheson, B.D., Horning, S.J., Coiffier, B., et al. (1999) "Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas", J. Clin. Oncol., 17, 1244-1253.
14. Gately, S. and Kerbel, R. (2003) "Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis", Prog. Exp. Tumor Res., 37, 179-192.
15. Tsujii, M., Kawano, S. and Dubois, R.N. (1997) "Cyclooxgenase-2 expression in human colon cancer cells increases metastatic potential", Proc. Natl. Acad. Sci. USA, 94, 3336-3340.
16. Hwang, D., Scollard, D., Byrne, J. and Levine, E. (1998) "Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer", J. Natl. Cancer Inst., 90, 455-460.
17. Uefuji, K., Ichikura, T., Mochizuki, H. and Shinomiya, N. (1998) "Expression of cyclooxygenase-2 protein in gastric adenocarcinoma", J. Surg. Oncol., 69, 168-172.
18. Eberhart, C.E., Coffey, R.J., Radhika, A., et al. (1994) "Upregulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas", Gastroenterology, 107(4), 1183-1188.
19. Tsujii, M., Kawano, S., Tsujii, S., et al. (1998) "Cyclooxygenase regulates angiogenesis induced by colon cancer cells", Cell, 93(5), 705-716.
20. Bellosillo, B., Pique, M., Barragan, M. et al. (1998) "Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells", Blood, 92(4), 1406-1414.
21. Klampfer, L., Cammenga, J., Wisniewski, H.G. and Nimer, S.D. (1999) "Sodyum salicylate activates caspase and induces apoptosis of myeloid leukemia cell lines", Blood, 93(7), 2386-2394.
22. Graf, B,A., Nazarenko, D.A., Borrello, M.A., et al. (1999) "Biphenotypic B/macrophage cells express cox-1 and up-regulate cox-2 expression and prostaglandin E2 production in response to pro-inflammatory signals", Eur. J. Immunol., 29, 3793-3803.
23. Biederbeck, A.B., Holly, E.A., Sturkenboom, M., et al. (2003) "Prescription medications associated with a decreased risk of non-Hodgkin's lymphoma", Am. J. Epidemiol., 157, 510-516.
24. Liu, X.H., Yao, S., Kirschenbaum, A. and Levine, A.C. (1998) "NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells", Cancer Res., 58(19), 4245-4249.
25. Dinarello, C.A. and Bunn, P.A. (1997) "Fever", Semin. Oncol., 24(3), 288-298.
26. Foss, H.D., Aravjo, I., Demel, G., et al. (1997) "Expression of vascular endothelial growth factor in lymphomas and Castleman disease", J. Pathol., 183, 44-50.
27. List, A.F. (2001) "Vascular endothelial growth factor signaling pathway as an emerging target in hematological malignancies", Oncologist, 6(suppl 5), 24-31.
28. Hazar, B., Paydas, S., Zorludemir, S., et al. (2003) "Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma", Leuk. Lymphoma, 44(12), 2089-2093.
29. Williams, C.S., Tsujii, M., Reese, J., et al. (2000) "Host cyclooxygenase-2 modulates carcinoma growth", J. Clin. Invest., 105, 1589-1594.
30. Konturek, P.C., Konturck, S.J., Pierzchalski, P., et al. (2002) "Gastric MALT-lymphoma, gastrin and cyclooxygenase", Acta Gastroenterol. Belg. (abstract), 65(1), 17-23.